148054-65-3

Basic information

• Product Name: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE
• Synonyms: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE;(S)-a-Phenyl-1-piperidineethanamine 2HCl
• CAS NO: 148054-65-3
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 148054-65-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 313.0±22.0 °C(Predicted)
• Appearance: /
• Density: 1.020±0.06 g/cm3(Predicted)
• PKA: 10.47±0.10(Predicted)
• CAS DataBase Reference: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(148054-65-3)
• EPA Substance Registry System: (S)-ALPHA-PHENYL-1-PIPERIDINEETHANAMINE(148054-65-3)

Safety Data

• Hazardous Substances Data: 148054-65-3(Hazardous Substances Data)

Upstream product

• 889864-59-9 (S)-2-Amino-2-phenyl-1-piperidin-1-yl-ethanone 
• 7101-04-4 (E/Z)-1-(2-hydroximino-2-phenylethyl)piperidine 
• 110-89-4 piperidine 
• 117049-14-6 tert-butyl N-[(1S)-2-hydroxy-1-phenylethyl]carbamate 
• 20780-54-5 (S)-styrene oxide 
• 110143-62-9 (S)-(+)-<2-<(methylsulfonyl)oxy>-1-phenylethyl>carbamic acid 1,1-dimethylethyl ester 
• 20989-17-7 (2S)-2-phenylglycinol 
• 83829-03-2 (S)-1-phenyl-2-(piperidin-1-yl)ethan-1-ol 
• 154472-05-6 (2R)-(-)-2-phenyl-2-(piperidin-1-yl)ethanol 
• 136412-37-8 ((S)-2-Oxo-1-phenyl-2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester 
• 5491-18-9 (S)-N-(benzyloxycarbonyl)phenylglycine 

Downstream Products

• 1039631-76-9 N-(tert-butoxycarbonyl)-3-(S)-(1-(S)-phenyl-2-N'-piperidinylethyl)aminopyrrolidine 
• 148076-28-2 Methyl-[((S)-2-oxo-1-phenyl-2-piperidin-1-yl-ethylcarbamoyl)-methyl]-carbamic acid benzyl ester 
• 1629873-34-2 (S)-N-benzhydryl-1-phenyl-2-(piperidin-1-yl)ethanamine 

Relevant articles and documents

COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF

Compounds of formula (I) and salts and solvates are provided wherein R2 is selected from phenyl substituted with n R1 groups, and pyridyl substituted with n R1 groups; n = 0, 1 or 2; each R1 is independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano; R3 is selected from hydrogen and C1-2 alkyl; R4 is selected from the group consisting of ethyl, n- propyl, i-propyl, n-butyl, i-butyl and t-butyl; or R3 and R4 together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered heterocyclic ring optionally substituted with one or more groups X; each X is independently selected from the group consisting of C1-4alkyl, and haloC1-4alkyl; R12 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl and methylthio; R13 is selected from hydrogen, chloro and trifluoromethyl; R14 is selected from hydrogen, trifluoromethyl and chloro; R15 is selected from hydrogen, chloro and trifluoromethyl; R16 is selected from hydrogen, methyl, fluoro and chloro; R12, R13, R14, R15 and R16 not all simultaneously being hydrogen. Processes for the preparation and uses of the compounds as medicaments for treating disorders such as psychoses, dementia or attention deficit disorder are also disclosed.

Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action

A series of benzoxazolamine and benzothiazolamine analogs that inhibit leukotriene (LT) biosynthesis are described.The initial lead, (S)-N-(benzothiazol-2-yl)phenylalanine ethyl ester (5a), was discovered in a screening program for inhibition of Ca-ionophore-A23187-induced LTB4 release in human polymorphonuclear leukocytes (IC50 0.23 μM).Through structural modification, it was determined that hydrophobic substituents in the 5-position and replacement of the phenyl ring of phenylalanine with a cyclohexyl group greatly enhance potency.Several ester bioisosteres that retain potency and enantiomeric selectivity are described.Lead optimization culminated in (S)-N--5-methyl-2-benzoxazolamine (43b), IC50 0.001 μM.The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.